🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Novartis expands radiotherapy manufacturing network with $85M plant in China fiercepharma.com/manufacturing/…

'Fascinating and completely unexpected': Tiny 'superbots' heal neural wound model fiercebiotech.com/research/fasci…

Intrigued by Novartis and Lilly deals, investors pour money into radiopharmaceuticals fiercebiotech.com/biotech/intrig…

advancedsciencenews.com/a-nanoparticle…

A wonderful festive season and a great start to 2024 from Louie and Luca and the rest of the Hagemeyer family!

Happy New Year, all the best for 2024!

Cytokinetics' heart failure drug improves exercise capacity, sending shares soaring in long-awaited win fiercebiotech.com/biotech/cytoki…

Novartis expands Pluvicto manufacturing footprint with FDA blessing of Indianapolis radiotherapy facility fiercepharma.com/manufacturing/…

Back to work in my old yet new role without the “acting” 😉. Bring on 2024 and many exciting imaging projects!

WuXi XDC, hot off $520M IPO, inks antibody-drug conjugate deal with Celltrion fiercepharma.com/pharma/wuxi-xd…

CAR-Ts turn back the clock on metabolic aging in mice—and even prevent it fiercebiotech.com/research/car-t…

CSL's 'most ambitious' phase 3 trial ends in failure for heart attack drug fiercebiotech.com/biotech/csls-m…

Sana's engineered pancreatic islet cells control blood sugar in monkey model of Type 1 diabetes fiercebiotech.com/research/sanas…

Australia's Noumed Pharma breaks ground on $65M manufacturing plant fiercepharma.com/manufacturing/…

#NewPaper supported by NIF Monash Biomedical Imaging Alfred Research Alliance: Molecular Imaging of Diffuse Cardiac Fibrosis with a Radiotracer That Targets Proteolyzed Collagen IV doi.org/10.1148/ryct.2… Rong XU Christoph Hagemeyer NanoTheranostics

New therapy cuts lipoprotein (a) by 99%: thelimbic.com/cardiology/new…

The challenges faced by early career researchers lens.monash.edu/@medicine-heal… #MonashLens

With $290M in hand, newly emerged biotech Metsera thinks customizable combos are the future of obesity treatments fiercebiotech.com/biotech/290m-h…

Novartis pays PeptiDream $180M as radiopharma big bang continues fiercebiotech.com/biotech/novart…

Tracer targets COX-2, reveals brain inflammation cen.acs.org/synthesis/radi… via C&EN (Chemical & Engineering News)